Impact of Early Intensive Reinduction Therapy on Event-Free Survival in Children with Low-Risk Acute Lymphoblastic Leukemia

  • G. Henze
  • R. Fengler
  • A. Reiter
  • J. Ritter
  • H. Riehm
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 33)


Since 1970, the basic concept of the Berlin-Frankfurt-Münster (BFM) study group trials for childhood acute lymphoblastic leukemia (ALL) has been intensified and prolonged induction and consolidation chemotherapy [9, 10]. In 1976, a trial was started with the aim of improving the prognosis of patients with high risk for relapse features, mainly characterized by an elevated WBC ≥25000/mm3. After successful remission induction these patients received an intensive reinduction protocol of 6 weeks duration early in remission, i.e., during the first 6 months after diagnosis, which increased the event-free survival (EFS) by about 30% compared with the historical control group of study ALL BFM 70 [3].


Acute Lymphoblastic Leukemia Historical Control Group Childhood Acute Lymphoblastic Leukemia Continuous Complete Remission Patient Complete Remission 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Abromowitch M, Ochs J, Pui CH, Kalwinsky D, Rivera GK, Fairclough D, Look T, Hustu HO, Murphy SB, Evans WE, Dahl GV, Bowman WP (1988) High-dose methotrexate improves clinical outcome in children with acute lymphoblastic leukemia: St Jude Therapy Study X. Med Pediatr Oncol 16: 297-303Google Scholar
  2. 2.
    Clavell LA, Gelber RD, Cohen HJ, Hitch-cock-Bryan S, Cassady JR, Tarbell NJ, Blattner SR, Tantravahi R, Leavitt P, Sallan SE (1986) Four-agent induction and intensive as-paraginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 315: 657 - 663PubMedCrossRefGoogle Scholar
  3. 3.
    Henze G, Langermann HJ, Ritter J, Schellong G, Riehm H (1981) Treatment strategy for different risk groups in childhood acute lymphoblastic leukemia: a report from the BFM-study group. Haematol Bluttransfus 26: 87 - 93Google Scholar
  4. 4.
    Henze G, Langermann HJ, Bramswig J, Breu H, Gadner H, Schellong G, Welte K, Riehm H (1981) Ergebnisse der Studie BFM 76/79 zur Behandlung der akuten lymphoblastischen Leukamie bei Kindern und Jugendlichen. Klin Padiatr 193: 145 - 154PubMedCrossRefGoogle Scholar
  5. 5.
    Henze G, Langermann HJ, Fengler R, Brandeis M, Evers KG, Gadner H, Hinder- feld L, Jobke A, Kornhuber B, Lampert F, Lasson U, Ludwig R, Muller-Weihrich S, Neidhardt M, Nessler G, Niethammer D, Rister M, Ritter J, Schaaff A, Schellong G, Stollmann B, Treuner J, Wahlen W, Weinel P, Wehinger H, Riehm H (1982) Therapiestudie BFM 79/81 zur Behandlung der akuten lymphatischen Leukamie bei Kindern und Jugendlichen: Intensivierte Reinduktionsthera- pie fur Patientengruppen mit unterschied- lichem Rezidivrisiko. Klin Padiatr 194:195- 203Google Scholar
  6. 6.
    Janka-Schaub G, Winkler K, Gobel U, Graubner U, Schwenger M, Haas RJ, Jiirgens H, Spaar J (1988) Kooperative Studie COALL-85 fur Risikopatienten mit akuter lymphatischer Leukamie: Erste Ergebnisse. Klin Padiatr 200: 171-176Google Scholar
  7. 7.
    Langermann HJ, Henze G, Wulf M, Riehm H (1982) Abschatzung der Tumorzellmasse bei der akuten lymphoblastischen Leukamie im Kindesalter: prognostische Bedeutung und praktische Anwendung. Klin Padiatr 194: 209 - 213PubMedCrossRefGoogle Scholar
  8. 8.
    Miller DR, Leikin S, Albo V, Sather H, Karon M, Hammond D (1981) Intensive therapy and prognostic factors in acute lymphoblastic leukemia of childhood. Haematol Bluttransfus 26: 77 - 83Google Scholar
  9. 9.
    Riehm H, Gadner H, Welte K (1977) Die West-Berliner Studie zur Behandlung der akuten lymphoblastischen Leukamie des Kindes - Erfahrungsbericht nach 6 Jahren. Klin Padiatr 189: 89 - 101PubMedGoogle Scholar
  10. 10.
    Riehm H, Gadner H, Henze G, Langermann HJ, Odenwald E (1980) The Berlin Childhood acute lymphoblastic leukemia therapy study 1970-1976. Am J Pediatr Hematol Oncol 2; 4: 299 - 306Google Scholar
  11. 11.
    Simone JV (1976) Factors that influence haematological remission duration in acute lymphocytic leukemia. Br J Haematol 32: 465 - 469PubMedCrossRefGoogle Scholar
  12. 12.
    Steinherz PG, Gaynon P, Miller DR, Rea- man G, Bleyer A, Finklstein J, Evans RG, Meyers P, Steinherz LJ, Sather H, Hammond D (1986) Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen - a new intensive therapy protocol: a report from the Children’s Cancer Study Group. J Clin Oncol 4: 744 - 752PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • G. Henze
    • 1
  • R. Fengler
    • 1
  • A. Reiter
    • 2
  • J. Ritter
    • 3
  • H. Riehm
    • 2
  1. 1.Dept. of PediatricsFree University of BerlinGermany
  2. 2.Dept. of PediatricsMedical SchoolHannoverGermany
  3. 3.Dept. of PediatricsUniversity of MünsterGermany

Personalised recommendations